ログイン
言語:

WEKO3

  • トップ
  • コミュニティ
  • ランキング
AND
To
lat lon distance
To

Field does not validate



インデックスリンク

インデックスツリー

メールアドレスを入力してください。

WEKO

One fine body…

WEKO

One fine body…

アイテム

{"_buckets": {"deposit": "7d8b1b30-65c0-4946-9072-be9c91b72e14"}, "_deposit": {"id": "9082", "owners": [], "pid": {"revision_id": 0, "type": "depid", "value": "9082"}, "status": "published"}, "_oai": {"id": "oai:nagoya.repo.nii.ac.jp:00009082"}, "item_10_alternative_title_19": {"attribute_name": "\u305d\u306e\u4ed6\u306e\u8a00\u8a9e\u306e\u30bf\u30a4\u30c8\u30eb", "attribute_value_mlt": [{"subitem_alternative_title": "Gene Therapy for Glioma"}]}, "item_10_biblio_info_6": {"attribute_name": "\u66f8\u8a8c\u60c5\u5831", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2002-08", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "8", "bibliographicPageEnd": "520", "bibliographicPageStart": "515", "bibliographicVolumeNumber": "11", "bibliographic_titles": [{"bibliographic_title": "\u8133\u795e\u7d4c\u5916\u79d1\u30b8\u30e3\u30fc\u30ca\u30eb"}]}]}, "item_10_description_4": {"attribute_name": "\u6284\u9332", "attribute_value_mlt": [{"subitem_description": "\u907a\u4f1d\u5b50\u6cbb\u7642\u306e\u81e8\u5e8a\u5fdc\u7528\u306f1990\u5e74,\u7c73\u56fd\u306b\u3066\u59cb\u307e\u3063\u305f.\u5f53\u521d\u306f\u907a\u4f1d\u5b50\u6b20\u640d\u306b\u3088\u308b\u5148\u5929\u6027\u75be\u60a3\u304c\u6cbb\u7642\u306e\u5bfe\u8c61\u3067\u3042\u3063\u305f\u304c,\u521d\u671f\u306e\u75c7\u4f8b\u3067\u306e\u5b89\u5168\u6027\u3084\u6709\u52b9\u6027\u304c\u5831\u544a\u3055\u308c\u308b\u3068,\u305d\u306e\u5bfe\u8c61\u75be\u60a3\u304c\u6025\u901f\u306b\u5e83\u304c\u308a,\u764c\u3084\u5f8c\u5929\u6027\u96e3\u6cbb\u6027\u75be\u60a3\u307e\u3067\u3082\u304c\u305d\u306e\u5bfe\u8c61\u75be\u60a3\u3068\u306a\u3063\u305f.\u764c\u306b\u5bfe\u3059\u308b\u907a\u4f1d\u5b50\u6cbb\u7642\u6cd5\u3068\u3057\u3066\u5b9f\u969b\u306b\u81e8\u5e8a\u5fdc\u7528\u3055\u308c\u3066\u3044\u308b\u65b9\u6cd5\u306f\u73fe\u5728\u307e\u3067\u306e\u3068\u3053\u308d,\u764c\u7d30\u80de\u306e\u7570\u5e38\u306a\u907a\u4f1d\u5b50\u3092\u6b63\u5e38\u5316\u3059\u308b\u907a\u4f1d\u5b50\u4fee\u5fa9\u6cbb\u7642,\u764c\u7d30\u80de\u306e\u7d30\u80de\u6b7b\u3084\u5897\u6b96\u6291\u5236\u306b\u95a2\u3059\u308b\u907a\u4f1d\u5b50\u3092\u5c0e\u5165\u3059\u308b\u65b9\u6cd5,\u3042\u308b\u3044\u306f\u764c\u514d\u75ab\u3092\u8ce6\u6d3b\u3059\u308b\u907a\u4f1d\u5b50\u3092\u5c0e\u5165\u3059\u308b\u907a\u4f1d\u5b50\u88dc\u5145\u7642\u6cd5\u306a\u3069\u304c\u3042\u3052\u3089\u308c\u308b.\u672c\u7a3f\u3067\u306f,\u81e8\u5e8a\u5fdc\u7528\u3055\u308c\u305f\u304b\u3042\u308b\u3044\u306f\u81e8\u5e8a\u6cbb\u9a13\u306e\u7533\u8acb\u304c\u51fa\u3055\u308c\u3066\u3044\u308b\u907a\u4f1d\u5b50\u6cbb\u7642\u6cd5\u306b\u3064\u3044\u3066\u6982\u8aac\u3059\u308b\u3068\u3068\u3082\u306b,\u7279\u306b\u8133\u816b\u760d\u9818\u57df\u3067\u306e\u907a\u4f1d\u5b50\u6cbb\u7642\u306e\u81e8\u5e8a\u5fdc\u7528\u306e\u6982\u7565\u3092\u5448\u793a\u3057,\u3055\u3089\u306b\u308f\u308c\u308f\u308c\u304c2000\u5e744\u6708\u3088\u308a\u81e8\u5e8a\u7814\u7a76\u3092\u958b\u59cb\u3057\u3066\u3044\u308b\u6b63\u96fb\u8377\u30ea\u30dd\u30bd\u30fc\u30e0\u3092\u7528\u3044\u305f\u8133\u816b\u760d\u306b\u5bfe\u3059\u308b\u30d2\u30c8\u03b2\u578b\u30a4\u30f3\u30bf\u30fc\u30d5\u30a7\u30ed\u30f3\u907a\u4f1d\u5b50\u306b\u3088\u308b\u30b5\u30a4\u30c8\u30ab\u30a4\u30f3\u907a\u4f1d\u5b50\u7642\u6cd5\u306e\u81e8\u5e8a\u7d4c\u9a13\u306b\u3064\u3044\u3066\u8ff0\u3079,\u307e\u305f\u4eca\u5f8c\u306e\u8133\u816b\u760d\u306e\u907a\u4f1d\u5b50\u6cbb\u7642\u306e\u65b9\u5411\u6027\u306b\u3064\u3044\u3066\u3082\u6982\u8aac\u3057\u305f. The first authorized human gene therapy was performed in the United States in 1990 on a patient with a defective adenosine deaminase (ADA) gene. Since this successful treatment, a variety of human gene therapy protocols have occurred worldwide. At present, more than 3,000 patients are enrolled in more than 500 protocols. Target diseases for gene therapy are expanding to encompass aquired life-threatening diseases such as cancer. As for brain tumors, especially for malignant gliomas, two major gene therapy approaches have been applied; 1. Suicide gene therapy using the herpes simplex virus thymidine kinase (HSV-tk) gene and ganciclovir, and 2. Immune gene therapy using cytokine genes. In the case of immune gene therapy, our team of neurosurgeons at Nagoya University developed a new form of treatment using the cationic liposome entrapped human interferon-beta gene, and use of this clinical protocol commenced in April, 2000.", "subitem_description_type": "Abstract"}]}, "item_10_identifier_60": {"attribute_name": "URI", "attribute_value_mlt": [{"subitem_identifier_type": "HDL", "subitem_identifier_uri": "http://hdl.handle.net/2237/10847"}]}, "item_10_publisher_32": {"attribute_name": "\u51fa\u7248\u8005", "attribute_value_mlt": [{"subitem_publisher": "\u65e5\u672c\u8133\u795e\u7d4c\u5916\u79d1\u30b3\u30f3\u30b0\u30ec\u30b9"}]}, "item_10_relation_43": {"attribute_name": "\u7570\u7248\u3067\u3042\u308b", "attribute_value_mlt": [{"subitem_relation_type": "isVersionOf", "subitem_relation_type_id": {"subitem_relation_type_id_text": "http://ci.nii.ac.jp/naid/110003812427/", "subitem_relation_type_select": "URI"}}]}, "item_10_rights_12": {"attribute_name": "\u6a29\u5229", "attribute_value_mlt": [{"subitem_rights": "\u65e5\u672c\u8133\u795e\u7d4c\u5916\u79d1\u30b3\u30f3\u30b0\u30ec\u30b9"}, {"subitem_rights": "\u672c\u6587\u30c7\u30fc\u30bf\u306f\u5b66\u5354\u4f1a\u306e\u8a31\u8afe\u306b\u57fa\u3065\u304dCiNii\u304b\u3089\u8907\u88fd\u3057\u305f\u3082\u306e\u3067\u3042\u308b"}]}, "item_10_select_15": {"attribute_name": "\u8457\u8005\u7248\u30d5\u30e9\u30b0", "attribute_value_mlt": [{"subitem_select_item": "publisher"}]}, "item_10_source_id_7": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "0917950X", "subitem_source_identifier_type": "ISSN"}]}, "item_10_text_14": {"attribute_name": "\u30d5\u30a9\u30fc\u30de\u30c3\u30c8", "attribute_value_mlt": [{"subitem_text_value": "application/pdf"}]}, "item_creator": {"attribute_name": "\u8457\u8005", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "\u82e5\u6797, \u4fca\u5f66"}], "nameIdentifiers": [{"nameIdentifier": "25475", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "\u4e2d\u539f, \u7d00\u5143"}], "nameIdentifiers": [{"nameIdentifier": "25476", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "\u6c34\u91ce, \u6b63\u660e"}], "nameIdentifiers": [{"nameIdentifier": "25477", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "\u68b6\u7530, \u6cf0\u4e00"}], "nameIdentifiers": [{"nameIdentifier": "25478", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "\u5409\u7530, \u7d14"}], "nameIdentifiers": [{"nameIdentifier": "25479", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Wakabayashi, Toshihiko"}], "nameIdentifiers": [{"nameIdentifier": "25480", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Nakahara, Norimoto"}], "nameIdentifiers": [{"nameIdentifier": "25481", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kajita, Yasukazu"}], "nameIdentifiers": [{"nameIdentifier": "25482", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Mizuno, Masaaki"}], "nameIdentifiers": [{"nameIdentifier": "25483", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Yoshida, Jun"}], "nameIdentifiers": [{"nameIdentifier": "25484", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "\u30d5\u30a1\u30a4\u30eb\u60c5\u5831", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2018-02-19"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "wakabayashi_1026.pdf", "filesize": [{"value": "656.7 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 656700.0, "url": {"label": "wakabayashi_1026.pdf", "url": "https://nagoya.repo.nii.ac.jp/record/9082/files/wakabayashi_1026.pdf"}, "version_id": "e8a77959-99d3-454c-8de5-ba7dc000d06d"}]}, "item_keyword": {"attribute_name": "\u30ad\u30fc\u30ef\u30fc\u30c9", "attribute_value_mlt": [{"subitem_subject": "glioma", "subitem_subject_scheme": "Other"}, {"subitem_subject": "gene therapy", "subitem_subject_scheme": "Other"}, {"subitem_subject": "clinical trial", "subitem_subject_scheme": "Other"}, {"subitem_subject": "herpes simplex virus thymidine kinase (HSV-tk)", "subitem_subject_scheme": "Other"}, {"subitem_subject": "cytokine", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "\u8a00\u8a9e", "attribute_value_mlt": [{"subitem_language": "jpn"}]}, "item_resource_type": {"attribute_name": "\u8cc7\u6e90\u30bf\u30a4\u30d7", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "\u30b0\u30ea\u30aa\u30fc\u30de\u306e\u907a\u4f1d\u5b50\u6cbb\u7642", "item_titles": {"attribute_name": "\u30bf\u30a4\u30c8\u30eb", "attribute_value_mlt": [{"subitem_title": "\u30b0\u30ea\u30aa\u30fc\u30de\u306e\u907a\u4f1d\u5b50\u6cbb\u7642"}]}, "item_type_id": "10", "owner": "1", "path": ["499/500/501"], "permalink_uri": "http://hdl.handle.net/2237/10847", "pubdate": {"attribute_name": "\u516c\u958b\u65e5", "attribute_value": "2009-01-21"}, "publish_date": "2009-01-21", "publish_status": "0", "recid": "9082", "relation": {}, "relation_version_is_last": true, "title": ["\u30b0\u30ea\u30aa\u30fc\u30de\u306e\u907a\u4f1d\u5b50\u6cbb\u7642"], "weko_shared_id": 3}
  1. C100 医学部/医学系研究科
  2. C100a 雑誌掲載論文
  3. 学術雑誌

グリオーマの遺伝子治療

http://hdl.handle.net/2237/10847
2263b259-80a9-47e0-8d12-1bbdffbe2c4d
名前 / ファイル ライセンス アクション
wakabayashi_1026.pdf wakabayashi_1026.pdf (656.7 kB)
Item type 学術雑誌論文 / Journal Article(1)
公開日 2009-01-21
タイトル
タイトル グリオーマの遺伝子治療
その他のタイトル
その他のタイトル Gene Therapy for Glioma
著者 若林, 俊彦

× 若林, 俊彦

WEKO 25475

若林, 俊彦

Search repository
中原, 紀元

× 中原, 紀元

WEKO 25476

中原, 紀元

Search repository
水野, 正明

× 水野, 正明

WEKO 25477

水野, 正明

Search repository
梶田, 泰一

× 梶田, 泰一

WEKO 25478

梶田, 泰一

Search repository
吉田, 純

× 吉田, 純

WEKO 25479

吉田, 純

Search repository
Wakabayashi, Toshihiko

× Wakabayashi, Toshihiko

WEKO 25480

Wakabayashi, Toshihiko

Search repository
Nakahara, Norimoto

× Nakahara, Norimoto

WEKO 25481

Nakahara, Norimoto

Search repository
Kajita, Yasukazu

× Kajita, Yasukazu

WEKO 25482

Kajita, Yasukazu

Search repository
Mizuno, Masaaki

× Mizuno, Masaaki

WEKO 25483

Mizuno, Masaaki

Search repository
Yoshida, Jun

× Yoshida, Jun

WEKO 25484

Yoshida, Jun

Search repository
権利
権利情報 日本脳神経外科コングレス
権利
権利情報 本文データは学協会の許諾に基づきCiNiiから複製したものである
キーワード
主題Scheme Other
主題 glioma
キーワード
主題Scheme Other
主題 gene therapy
キーワード
主題Scheme Other
主題 clinical trial
キーワード
主題Scheme Other
主題 herpes simplex virus thymidine kinase (HSV-tk)
キーワード
主題Scheme Other
主題 cytokine
抄録
内容記述 遺伝子治療の臨床応用は1990年,米国にて始まった.当初は遺伝子欠損による先天性疾患が治療の対象であったが,初期の症例での安全性や有効性が報告されると,その対象疾患が急速に広がり,癌や後天性難治性疾患までもがその対象疾患となった.癌に対する遺伝子治療法として実際に臨床応用されている方法は現在までのところ,癌細胞の異常な遺伝子を正常化する遺伝子修復治療,癌細胞の細胞死や増殖抑制に関する遺伝子を導入する方法,あるいは癌免疫を賦活する遺伝子を導入する遺伝子補充療法などがあげられる.本稿では,臨床応用されたかあるいは臨床治験の申請が出されている遺伝子治療法について概説するとともに,特に脳腫瘍領域での遺伝子治療の臨床応用の概略を呈示し,さらにわれわれが2000年4月より臨床研究を開始している正電荷リポソームを用いた脳腫瘍に対するヒトβ型インターフェロン遺伝子によるサイトカイン遺伝子療法の臨床経験について述べ,また今後の脳腫瘍の遺伝子治療の方向性についても概説した. The first authorized human gene therapy was performed in the United States in 1990 on a patient with a defective adenosine deaminase (ADA) gene. Since this successful treatment, a variety of human gene therapy protocols have occurred worldwide. At present, more than 3,000 patients are enrolled in more than 500 protocols. Target diseases for gene therapy are expanding to encompass aquired life-threatening diseases such as cancer. As for brain tumors, especially for malignant gliomas, two major gene therapy approaches have been applied; 1. Suicide gene therapy using the herpes simplex virus thymidine kinase (HSV-tk) gene and ganciclovir, and 2. Immune gene therapy using cytokine genes. In the case of immune gene therapy, our team of neurosurgeons at Nagoya University developed a new form of treatment using the cationic liposome entrapped human interferon-beta gene, and use of this clinical protocol commenced in April, 2000.
内容記述タイプ Abstract
出版者
出版者 日本脳神経外科コングレス
言語
言語 jpn
資源タイプ
資源タイプresource http://purl.org/coar/resource_type/c_6501
タイプ journal article
関連情報
関連タイプ isVersionOf
関連識別子
識別子タイプ URI
関連識別子 http://ci.nii.ac.jp/naid/110003812427/
ISSN
収録物識別子タイプ ISSN
収録物識別子 0917950X
書誌情報 脳神経外科ジャーナル

巻 11, 号 8, p. 515-520, 発行日 2002-08
フォーマット
application/pdf
著者版フラグ
値 publisher
URI
識別子 http://hdl.handle.net/2237/10847
識別子タイプ HDL
戻る
0
views
See details
Views

Versions

Ver.1 2021-03-01 12:05:17.835086
Show All versions

Share

Mendeley CiteULike Twitter Facebook Print Addthis

Cite as

Export

OAI-PMH
  • OAI-PMH JPCOAR
  • OAI-PMH DublinCore
  • OAI-PMH DDI
Other Formats
  • JSON
  • BIBTEX

Confirm


Powered by CERN Data Centre & Invenio


Powered by CERN Data Centre & Invenio